Cumberland Pharmaceuticals Inc.
CPIX · Nasdaq · United States
Share price · CPIX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CPIX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026+12.8%
Nothing announced by CPIX that day or the session before.
- 26 Oct 2026-48.8%
- 20 Oct 2026+18.8%
- 31 Aug 2026-20.9%
- Day beforeRegulation FD disclosure
- 2 Jul 2026-10.7%
- 26 Jun 2026+13.3%
- 15 May 2026+11.2%
Nothing announced by CPIX that day or the session before.
- 23 Apr 2026+27.9%
- 4 Mar 2026-19.9%
- 6 Jan 2026+18.0%
Nothing announced by CPIX that day or the session before.
Share of unusual movement by asset
For each asset, the share of CPIX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Ifetrobanevents and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 24% |
| Other company news (earnings, financing, releases naming no asset) | — | 26% |
| Sessions with no dated event | — | 50% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Thromboxane A2 receptor (TP receptor) | Systemic Sclerosis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $0.8M | $81M | —-$1.5M operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $8.8M | $0.8M | $3.9M | $4.3M$0.2M operating cash flow | report ↗ |
| 2026-Q1 | $9.1M | $1.5M | $11M | $3.3M$0.4M operating cash flow | report ↗ |
| 2025-Q4 | $14M | — | $11M | $1.4M$0 operating cash flow | report ↗ |
| 2025-Q3 | $8.3M | $1.3M | $15M | $1.9M$0.2M operating cash flow | report ↗ |
| 2025-Q2 | $11M | $1.5M | $16M | $0.7M$0.8M operating cash flow | report ↗ |
| 2025-Q1 | $12M | $1.3M | $15M | —$3.9M operating cash flow | report ↗ |
| 2024-Q4 | $10M | — | $18M | $1.9M$1.9M operating cash flow | report ↗ |
| 2024-Q3 | $9.1M | $1.3M | $17M | $1.5M$0.5M operating cash flow | report ↗ |
| 2024-Q2 | $9.8M | $1.1M | $17M | $1.1M-$0.9M operating cash flow | report ↗ |
| 2024-Q1 | $8.5M | $1.2M | $19M | $1.9M-$2.1M operating cash flow | report ↗ |
| 2023-Q4 | $9.3M | — | $18M | $6.3M$1.0M operating cash flow | report ↗ |
| 2023-Q3 | $10M | $1.9M | $19M | $1.1M$1.2M operating cash flow | report ↗ |
| 2023-Q2 | $11M | $1.1M | $18M | —$5.2M operating cash flow | report ↗ |
| 2023-Q1 | $9.2M | $1.5M | $16M | —-$1.4M operating cash flow | report ↗ |
| 2022-Q4 | $9.1M | — | $20M | $2.4M$3.6M operating cash flow | report ↗ |
| 2022-Q3 | $11M | $1.7M | $20M | $0.4M$2.6M operating cash flow | report ↗ |
| 2022-Q2 | $10M | $1.8M | $18M | $1.3M$2.3M operating cash flow | report ↗ |
| 2022-Q1 | $11M | $1.8M | $17M | $1.4M-$0.1M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $27M | $3.9M$2.0M operating cash flow | report ↗ |
| 2021-Q3 | $8.1M | $1.4M | $26M | $1.1M-$0.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $45M | $5.6M | $11M | $0.7M$4.9M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-03-18 | KAZIMI A J · director, Chairman and CEO, 10% owner | Award / grant (derivative) | 100,000 | $2.80 | $280K | Form 4 |
| 2026-03-18 | Herman James L · VP and Chief Compliance Office | Award / grant (derivative) | 2,500 | $2.80 | $7K | Form 4 |
| 2026-03-18 | Hamm John M. · VP Chief Financial Officer | Award / grant (derivative) | 3,000 | $2.80 | $8K | Form 4 |
| 2026-03-18 | Bitterman Chris T. · Vice Pres Sales & Marketing | Award / grant (derivative) | 3,000 | $2.80 | $8K | Form 4 |
| 2026-03-18 | Anthony Todd M. · Vice Pres Organizational Dev | Award / grant (derivative) | 3,000 | $2.80 | $8K | Form 4 |
| 2026-03-18 | Young Caroline · director | Award / grant | 1,800 | $2.80 | $5K | Form 4 |
| 2026-03-18 | Krogulski Kenneth · director | Award / grant | 1,800 | $2.80 | $5K | Form 4 |
| 2026-03-18 | Jones James · director | Award / grant | 1,800 | $2.80 | $5K | Form 4 |